Serina Therapeutics Reports Full Year 2024 Financial Results and Recent Business Highlights
Provided By GlobeNewswire
Last update: Mar 24, 2025
HUNTSVILLE, March 24, 2025 (GLOBE NEWSWIRE) -- Serina Therapeutics, Inc. (“Serina”) (NYSE American: SER), a clinical-stage biotechnology company developing its proprietary POZ Platform™ drug optimization technology, today reported its financial results for the full year ended December 31, 2024 and provided recent business highlights.
Read more at globenewswire.com
